Українська English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2024; 70(3): 16-26


THE METABOLIC EFFECT OF CELLULAR PROTEIN KINASES BLOCKADE ON THE EXPERIMENTAL DIABETES

S.V. Ziablitzev1, K.O. Usenko1, O.V. Dobrovinska2, Yu.V. Perepelytsa1, V.A. Andrushchenko1

  1. Bogomoletz National Medical University, Kyiv, Ukraine
  2. V.P. Komisarenko Institute of Endocrinology and Metabolism, Kyiv, Ukraine
DOI: https://doi.org/10.15407/fz70.03.016


Abstract

Prospective use of receptor protein kinase inhibitors (PKI) for the prevention and/or treatment of diabetic complications necessitates the study of their effect on carbohydrate, lipid, and protein metabolism in experimental models of type 1 (DM1) and type 2 (DM2) diabetes. DM1 was modeled in male Wistar rats with streptozotocin administration (50 mg/ kg), DM2 – by long-term (180 days) maintenance on a highcalorie fat diet (HFD; 56,7% fat) with the introduction of a lower dose of streptozotocin (25 mg/kg). For the treatment, we used insulin (“Actrapid Novo Nordisk”, Denmark) and a PKI inhibitor Sorafenib (“Cipla”, India), added orally in sachet form (150 mg/kg). Regardless of the diet type, the streptozotocin administration led to hyperglycemia, weight loss, glucose- and ketonuria, polyuria, and polydipsia. The severity of these manifestations was heightened in HFD rats, with a mortality rate of 53.3% observed (when modeling DM1 – 12%), likely attributed to the onset of liver failure. In HFD rats, slight hyperglycemia was noted only on the 150th day. All the diabetes models used were accompanied by significant hypercholesterolemia and hyperlipidemia. The addition of glucose to HFD rats increased the cholesterol content. HFD caused hypoproteinemia, metabolism suppression and increased transaminases activity. The established violations were largely restored with the use of PKI: glycemia level, body weight loss, the content of triglycerides and very low-density lipoproteins decreased; an increase in high-density lipoproteins and the normalization of pigment metabolism were observed.

Keywords: hyperglycemia; fat diet; streptozotocin; steatohepatosis; hypoproteinemia; hypercholesterolemia; hypertriglyceridemia.

References

  1. Patterson CC, Karuranga S, Salpea P, Saeedi P, Dahlquist G, Soltesz G, Ogle GD. Worldwide estimates of incidence, prevalence and mortality of type 1 diabetes in children and adolescents: Results from the international diabetes federation diabetes atlas, 9th edition. Diabetes Res Clin Pract. 2019 Nov;157:107842. CrossRef PubMed
  2. Lovic D, Piperidou A, Zografou I, Grassos H, Pittaras A, Manolis A. The growing epidemic of diabetes mellitus. Curr Vascul Pharmacol. 2020;18(2):104-9. CrossRef PubMed
  3. Valaiyapathi B, Gower B, Ashraf AP. Pathophysiology of type 2 diabetes in children and adolescents. Curr Diabet Rev. 2020;16(3):220-9. CrossRef PubMed PubMedCentral
  4. Gheibi S, Kashfi K, Ghasemi A. A practical guide for induction of type-2 diabetes in rat: Incorporating a highfat diet and streptozotocin. Biomed Pharmacother. 2017 Nov;95:605-13. CrossRef PubMed
  5. Goyal SN, Reddy NM, Patil KR, Nakhate KT, Ojha S, Patil CR, Agrawal YO. Challenges and issues with streptozotocin-induced diabetes - A clinically relevant animal model to understand the diabetes pathogenesis and evaluate therapeutics. Chem Biol Interact. 2016 Jan 25;244:49-63. CrossRef PubMed
  6. Ghasemi A, Jeddi S. Streptozotocin as a tool for induction of rat models of diabetes: A practical guide. EXCLI J. 2023 Feb 21;22:274-94.
  7. Sharma M, Chan HK, Lavilla CA Jr, Uy MM, Froemming GRA, Okechukwu PN. Induction of a single dose of streptozotocin (50 mg) in rat model causes insulin resistance with type 2 diabetes mellitus. Fundam Clin Pharmacol. 2023 Aug;37(4):769-78. CrossRef PubMed
  8. Saha S, Fang X, Green CD, Das A. mTORC1 and SGLT2 Inhibitors-a therapeutic perspective for diabetic cardiomyopathy. Int J Mol Sci. 2023 Oct 11;24(20):15078. CrossRef PubMed PubMedCentral
  9. Zhang K, Li M, Yin K, Wang M, Dong Q, Miao Z, Guan Y, Wu Q, Zhou Y. Hyperoside mediates protection from diabetes kidney disease by regulating ROS-ERK signaling pathway and pyroptosis. Phytother Res. 2023 Dec;37(12):5871-82. CrossRef PubMed
  10. Mehrabadi ME, Salemi Z, Babaie S, Panahi M. Effect of biochanin a on retina levels of vascular endothelial growth factor, tumor necrosis factor-alpha and interleukin-1beta in rats with streptozotocin-induced diabetes. Can J Diabet. 2018 Dec;42(6):639-44. CrossRef PubMed
  11. Ziablitsev SV, Vodianyk VV, Dyadyk OO. The influence of tyrosine protein kinases blockade on the vasculonedothelial growth factor expression and diabetic retinopathy development. Fiziol Zh. 2023; 69(5): 22-32. [Ukrainian]. CrossRef
  12. Ziablitsev SV, Vodianyk VV. Retinal apoptosis and the effect of tyrosine kinase inhibition in experimental diabetes. J Ophthalmol. 2023;5(514):34-40. [Ukraine]. CrossRef
  13. Vodianyk VV, Ziablitsev SV, Andrushchenko VI. Effect of tyrosine protein kinase blockade on the state of retinal microglia in diabetic retinopathy. Int J Endocrinol. 2023;19(5):337-43. [Ukrainian]. CrossRef
  14. Wu C, Xu K, Liu W, Liu A, Liang H, Li Q, Feng Z, Yang Y, Ding J, Zhang T, Liu Y, Liu X, Zuo Z. Protective effect of Raf-1 kinase inhibitory protein on diabetic retinal neurodegeneration through P38-MAPK pathway. Curr Eye Res. 2022 Jan;47(1):135-42. CrossRef PubMed
  15. Striglia E, Caccioppo A, Castellino N, Reibaldi M, Porta M. Emerging drugs for the treatment of diabetic retinopathy. Expert Opin Emerg Drug. 2020 Sep;25(3):261-71. CrossRef PubMed
  16. Boneva SK, Wolf J, Hajdú RI, Prinz G, Salié H, Schlecht A, et al. In-depth molecular characterization of neovascular membranes suggests a role for hyalocyte-tomyofibroblast transdifferentiation in proliferative diabetic retinopathy. Front Immunol. 2021 Nov 2;12:757607. CrossRef PubMed PubMedCentral
  17. Natrus LV, Osadchuk YuS, Labudzinskyi DO, Chaikovsky YuB, Smirnov AS. The pathogenetic rationale the ways of experimental type 2 diabetes mellitus modeling. Med Sci Ukraine. 2019;3-4(15):10-18. [Ukrainian]. CrossRef
  18. Oraby MA, El-Yamany MF, Safar MM, Assaf N, Ghoneim HA. Dapagliflozin attenuates early markers of diabetic nephropathy in fructose-streptozotocin-induced diabetes in rats. Biomed Pharmacother. 2019 Jan;109:910-20. CrossRef PubMed
  19. Calorie table online, 2024 (Dine4FIT, Inc., Czech Republic) [Internet]. Available from://www.tablycjakalorijnosti. com.ua.
  20. Godik OS, Levytskii AF, Diehtiarova DS, Benzar IM, Korsak AV, Likhodiievskyi VV. Partial hepatic portal vein ligation: morphological assessment of prehepatic portal hypertension modeling. Pediatr Surg. 2023;1(78):59-65. [Ukraine]. CrossRef
  21. Perepelytsia YuV, Mikhnev VA, Krishtal MV, Trofimova IM. Influence of non-gaseous acidosis and alkalosis on the unlimited proteolysis of blood and tissues. Endokrynologia. 2021;26(1):42-8. [Ukrainian]. CrossRef
  22. Ayala JE, Bracy DP, Malabanan C, James FD, Ansari T, Fueger PT, McGuinness OP, Wasserman DH. Hyperinsulinemic-euglycemic clamps in conscious, unrestrained mice. J Vis Exp. 2011 Nov 16;(57):3188. CrossRef PubMed PubMedCentral
  23. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res. 2005 Oct;52(4):313-20. CrossRef PubMed
  24. Flanagan AM, Brown JL, Santiago CA, Aad PY, Spicer LJ, Spicer MT. High-fat diets promote insulin resistance through cytokine gene expression in growing female rats. J Nutr Biochem. 2008;8(19):505-13. CrossRef PubMed
  25. Abdelgalil AA, Alkahtani HM, Al-Jenoobi FI. Sorafenib. Profiles Drug Subst Excip Relat Methodol. 2019;44: 239-66. CrossRef PubMed
  26. Jian C, Fu J, Cheng X, Shen LJ, Ji YX, Wang X, Pan S, Tian H, et al. Low-dose sorafenib acts as a mitochondrial uncoupler and ameliorates nonalcoholic steatohepatitis. Cell Metab. 2020 May 5;31(5):892-908.e11. CrossRef PubMed PubMedCentral

© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2025.